IceCure Medical Ltd. (NASDAQ:ICCM) Given Consensus Rating of “Hold” by Brokerages

IceCure Medical Ltd. (NASDAQ:ICCM) has received an average recommendation of “Hold” from the five analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $62.70.

A number of brokerages recently weighed in on ICCM. Maxim Group decreased their price target on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of IceCure Medical to a “sell” rating in a research note on Sunday, July 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research note on Friday, July 17th. Finally, Alliance Global Partners initiated coverage on IceCure Medical in a report on Monday, May 4th. They set a “buy” rating on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ICCM. Jane Street Group LLC acquired a new position in shares of IceCure Medical in the fourth quarter valued at approximately $67,000. Concurrent Investment Advisors LLC purchased a new stake in shares of IceCure Medical during the fourth quarter worth approximately $48,000. Finally, Virtu Financial LLC acquired a new stake in shares of IceCure Medical during the fourth quarter worth $39,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

IceCure Medical Trading Up 7.0%

Shares of NASDAQ ICCM opened at $3.51 on Wednesday. The stock has a market cap of $12.04 million, a P/E ratio of -0.49 and a beta of 0.47. IceCure Medical has a twelve month low of $2.12 and a twelve month high of $42.00. The stock has a 50 day moving average of $4.03 and a two-hundred day moving average of $10.06.

IceCure Medical (NASDAQ:ICCM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%.The business had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $1.34 million. As a group, research analysts predict that IceCure Medical will post -3.51 earnings per share for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.